70% DEXTROSE INJECTION USP SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

DEXTROSE

可用日期:

BAXTER CORPORATION

ATC代码:

B05BA03

INN（国际名称）:

CARBOHYDRATES

剂量:

70G

药物剂型:

SOLUTION

组成:

DEXTROSE 70G

给药途径:

INTRAVENOUS

每包单位数:

500/1000/2000/3000ML

处方类型:

Ethical

治疗领域:

CALORIC AGENTS

產品總結:

Active ingredient group (AIG) number: 0102181015; AHFS:

授权状态:

APPROVED

授权日期:

1999-03-05

产品特点

Page 1 of 14
PRESCRIBING INFORMATION
50% DEXTROSE INJECTION, USP
70% DEXTROSE INJECTION, USP
IN PHARMACY BULK PACK
IV Fluid and Nutrient Replenisher
Baxter Corporation
Mississauga, Ontario L5N 0C2
Canada
Date of Revision:
November 21, 2018
Submission Control No: 220929
Baxter and Viaflex are trademarks of Baxter International Inc
.
Page 2 of 14
50% DEXTROSE INJECTION, USP/
70% DEXTROSE INJECTION, USP
NOT FOR DIRECT INFUSION
IN PHARMACY BULK PACK
SUMMARY PRODUCT INFORMATION
50% Dextrose Injection, USP and 70% Dextrose Injection, USP are
sterile, nonpyrogenic,
hypertonic solutions for fluid replenishment and caloric supply in a
Pharmacy Bulk Package. A
Pharmacy Bulk Package is a container of sterile preparation for
parenteral use that contains many
single doses. The contents are intended for use in a pharmacy
admixture program and are
restricted to the preparation of admixtures for intravenous infusion.
They contain no
antimicrobial agents. Composition, osmolarity, pH, and caloric content
are shown in Table 1.
TABLE 1. PRODUCT INFORMATION.
***
DEX
USP
G/L
OSMOLARITY
(MOSMOL/L)
*KCAL
/L
**KJ/
L
PH
CODE
VOLUM
E
50%
DEXTROSE
INJ USP
500
2520
1710
7147.8
4.0
2B0256
2000 mL
70%
DEXTROSE
INJ USP
700
3530
2380
9948.4
4.0
2B0296
2000 mL
70%
DEXTROSE
INJ USP
700
3530
2380
9948.4
4.0
JB0297
3000 mL
* Dex = 3.4 kcal/g
** 1 kcal = 4.18 kJ
*** the dextrose is purified from corn and may contain fructose
.
The structural formula of Dextrose Hydrous, USP is:
Page 3 of 14
The VIAFLEX plastic container is fabricated from a specially
formulated polyvinyl chloride (PL
146 Plastic) with di-2-ethylhexyl phthalate (DEHP) as a plasticizer.
Exposure to temperatures
above 25˚C during transport and storage will lead to minor losses in
moisture content. Higher
temperatures lead to greater losses. It is unlikely that these minor
losses will lead to clinically
significant changes within the expiration period. The amount of water
that can permeate from
inside the container into the overwrap is insufficient to affect the
solution significantly.